Outcome of Treatment of Chronic Hepatitis C Patients by New Antiviral Drugs
DOI:
https://doi.org/10.37506/ijphrd.v11i3.1557Keywords:
Direct-acting antiviral agents (DAAs); Hepatitis C virus; Side effects.Abstract
HCV constitutes a significant health burden worldwide. Hepatitis C is a disease with significant global
impact. Egypt has a high prevalence of HCV worldwide (>10%) . In Africa and the western Pacific the
prevalence (? 3%) is significantly higher than in North America and Europe (<2%). In general, everyone
with chronic HCV should receive antiviral therapy. This is because patients who are cured of their HCV
infection benefit from reduction in the risk of hepatocellular carcinoma, liver related mortality and even allcause
mortality.In general, everyone with chronic HCV should receive antiviral therapy, treatment should be
given first to patients with advanced fibrosis and high risk for liver-related complications. Also, patients with
severe extrahepatic HCV manifestations should be given high priority. The timing of treatment in patients
with mild liver disease can be individualized. This review provides insight into clinical studies of NS3/4A
protease inhibitors, NS5B viral polymerase inhibitor (nucleotide and non-nucleotide), and NS5A inhibitors,
alone and in combination.